Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB, Multi-center, Open Label Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With DMARDs in Patients With Active Rheumatoid Arthritis Who Participated in C87076.

NCT00843778 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00843778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00843778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB, Multi-center, Open Label Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With DMARDs in Patients With Active Rheumatoid Arthritis Who Participated in C87076.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2009
Completion date
December 31, 2012
Enrollment
131 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis